Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

Income Statement

Follow revenue through to earnings.

Revenue

$72.59M

FY 2025 · Annual

+105.8% YoY

Operating Income

-$247.72M

FY 2025 · Annual

Net Income

-$218.96M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.7M14.46M26.98M35.28M72.59M
Cost of Revenue00156.5M172.97M0
Gross Profit11.7M14.46M(129.52M)(137.69M)72.59M
Gross Margin100.0%100.0%-480.1%-390.3%100.0%
Research & Development44.88M81.61M156.5M172.97M240.28M
Selling, General & Admin32.44M49.51M59.83M71.46M80.02M
Operating Expenses77.32M131.12M60.43M72.18M320.3M
Depreciation & Amortization1.41M3.69M6.55M7.18M6.42M
EBITDA(64.09M)(107.21M)(169.4M)(164.89M)(212.18M)
EBITDA Margin-547.9%-741.3%-628.0%-467.4%-292.3%
Operating Income(65.62M)(116.65M)(189.95M)(209.87M)(247.72M)
Operating Margin-561.0%-806.6%-704.1%-595.0%-341.3%
Interest Income120K5.76M14M34.28M28.46M
Interest Expense2.98M3.34M3.26M1.73M206K
Other Income / Expenses(2.86M)2.41M10.74M36.08M28.91M
Income Before Tax(68.48M)(114.24M)(179.21M)(173.8M)(218.81M)
Pre-Tax Margin-585.5%-789.9%-664.3%-492.7%-301.4%
Income Tax Expense(1.66M)(1.52M)1.46M(4.77M)152K
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Net Margin-571.2%-779.3%-669.7%-479.2%-301.7%
EPS (Basic)(2.67)(3.80)(5.08)(2.91)(3.16)
EPS (Diluted)(2.67)(3.80)(5.08)(2.90)(3.16)
Weighted Avg Shares25.06M29.66M35.59M58.21M69.28M
Weighted Avg Shares (Diluted)25.06M29.66M35.59M58.21M69.28M

BCYC Earnings Waterfall · TTM

NASDAQ:BCYC · Revenue to Net Income

Key Ratios

EPS$-3.15
Gross Margin-508.1%
Net Margin-2526.7%
P/E Ratio-2.8
P/S Ratio146.3

Analysis

$63.5M of revenue converted into -$219.0M of net income for the selected period. Gross margin is -508.1% and net margin is -2526.7%, showing how much revenue survives after costs and taxes. EPS is $-3.15, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportOct 29, 2026
8-KCurrent reportOct 29, 2026
4/A4/A filingOct 7, 2026
4Statement of changes in beneficial ownershipOct 6, 2026
4Statement of changes in beneficial ownershipOct 6, 2026

How much revenue does BCYC generate?

Bicycle Therapeutics plc (BCYC) reported $72.59M of revenue in fiscal 2025.

Is BCYC profitable?

Bicycle Therapeutics plc (BCYC) reported -$218.96M of net income, with a net margin of -301.7%.